Form 4: Pfizer SVP & Controller Jennifer B. Damico Reports Acquisition of Phantom Stock Units
SEC Form 4 Filing
Jennifer B. Damico, SVP & Controller at Pfizer Inc., reported the acquisition of phantom stock units through the Pfizer Supplemental Savings Plan.
Summary
- On June 14, 2024, Jennifer B. Damico, SVP & Controller of Pfizer Inc., acquired 51 phantom stock units through the Pfizer Supplemental Savings Plan (SSP).
- Each unit represents one phantom share of Pfizer common stock.
- The price of the phantom stock units was $27.53.
- Following the transaction, Damico directly owns 28,475 derivative securities.
- These units are settled in cash following the reporting person's separation from service and may be transferred into an alternative investment account at any time.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing reporting an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock and related derivatives.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it involves phantom stock units and is part of standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of transaction: acquisition of phantom stock units |
| 06/17/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.